(1R,2R,6S)-2(4-(4-Isopropylbenzyl)piperazin-1-yl)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-enol

(1R,2R,6S)-2(4-(4-Isopropylbenzyl)piperazin-1-yl)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-enol Full article

Journal

MolBank
ISSN: 1422-8599

Output data

Year: 2023, Volume: 2023, Number: 1, Pages: M1546 Pages count : DOI: 10.3390/m1546

Tags

monoterpene; epoxide cycle opening; tertiary amine

Authors

Podturkina Alexandra V. ¹ , Li-Zhulanov Nikolai S. ¹ , Volcho Konstantin P. ¹ , Salakhutdinov Nariman F. ¹

Affiliations

1	N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch, Russian Academy of Sciences, Lavrentiev Avenue 9, 630090 Novosibirsk, Russia

Parkinson’s disease (PD) is a progressive neurodegenerative disorder mainly characterized by movement dysfunction. Earlier, it was found that (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol (Prottremin) demonstrated antiparkinsonian activity in vivo on different animal models of PD. The paper presents synthesis of new Prottremin derivative, (1R,2R,6S)-2(4-(4-isopropylbenzyl)piperazin-1-yl)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-enol. The derivative was obtained by epoxide ring opening reaction with 1-(4-isopropylbenzyl)piperazine. The product yield was 48% after purification.

Podturkina A.V. , Li-Zhulanov N.S. , Volcho K.P. , Salakhutdinov N.F.
(1R,2R,6S)-2(4-(4-Isopropylbenzyl)piperazin-1-yl)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-enol
MolBank. 2023. V.2023. N1. P.M1546. DOI: 10.3390/m1546 WOS РИНЦ

Submitted:	Dec 9, 2022
Accepted:	Jan 10, 2023
Published online:	Jan 12, 2023

Web of science	WOS:000958148800001
Elibrary	60316122
OpenAlex	W4315786548